Please note correction to spelling of choice A of question 16.
Managing the Spectrum of Premenstrual Symptoms
Continuing Pharmacy Education Accreditation /Ascend Media Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of 290-000-05-022-H01.
After reading "Managing the Spectrum of Premenstrual Symptoms," complete the program evaluation and select the 1 best answer to each of the following questions. A statement of continuing education hours will be mailed to those who successfully complete (with a minimum score of 70%) the examination at the conclusion of the program.
1. Identify which statement is NOT CORRECT in the following list of statements.
2. Work-productivity loss associated with PMS, in a study conducted over 2 menstrual cycles, indicated:
3. An estimated 2 million to 5 million reproductive-age women in the United States have symptoms of sufficient severity to be classified as PMDD. Applying population averages for years of reproductive life and numbers of pregnancies, this extrapolates to a lifetime total of roughly _______ years of severe symptoms.
4. According to the criteria established for PMDD by the American Psychiatric Association, reported in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, (DSM-IV-TR), a woman must experience at least 5 of 11 listed symptoms, including one or more of 4 "core" or "essential" symptoms. Which of the following is NOT among the essential symptoms?
5. Which of the following self-assessment tools is NOT among those used to assess PMS and/or PMDD?
6. PMDD symptoms must be present during most of the last week of the luteal phase in most, if not all, of the woman's menstrual cycles during the previous year. Which one of the following statements is NOT CORRECT?
7. Which of the following is true?
8. Current US Food and Drug Administration (FDA)-approved treatment options for PMDD are limited to:
9. Although the SSRIs that have FDA indications for PMDD have demonstrated efficacy for several PMDD symptoms, a frequency of 10% or more has been reported for the following side effect(s) with SSRIs:
10. In a study of compliance in taking prescribed antidepressant agents for PMS, 148 women started but 91 (61.5%) had discontinued the antidepressant by the end of 2 years. Among the primary reasons (Â³ 15%) were all of the following EXCEPT:
11. Gonadotropin-releasing hormone (GnRH) agonists can be used to suppress ovulation and effectively alleviate premenstrual symptoms. However, using GnRH agonists:
12. Another hormonally mediated drug, the synthetic androgen danazol, suppresses ovulation, but its use is limited by adverse effects, including:
13. In early studies, OCs have had mixed results in reducing premenstrual symptoms. However, more recent research indicates greater promise for low-dose formulations. Which of the following statements best reflects the results shown by recent studies?
14. In the female reproductive system, the degree of follicular activity during OC use is dependent on:
15. Current trends in the use of low-dose OCs, including the use of newer progestins in extended regimens, are being followed in pursuit of these potential benefits:
16. All but one of the progestins being used in OCs in the United States are derived from 19-nortestosterone. The exception, which has a pharmacologic profile closely resembling natural progesterone, is:
17. Drospirenone, unlike progestins used in most OCs:
18. During the preextension phase of a current study, women taking a variety of 19-nortestosterone-based progestins were switched to an OC containing ethinyl estradiol (EE) 30 Âµg plus drospirenone 3 mg for 2 cycles. As measured by DSR-17 (Daily Symptom Report) scores, the mean scores for cycles in which EE/drospirenone were taken:
19. Several recent studies that assess the efficacy of a new, low-dose OC (EE 20 Âµg, drospirenone 3 mg) on several somatic and affective scales have indicated the following.
20. A double-blind, placebo-controlled, parallel-group study of EE 20 Âµg, drospirenone 3 mg, using a 24/4 regimen in women with PMDD symptoms, was conducted over 3 treatment cycles. It showed improvements for the active drug in all groupings of the DRSP scale, beginning with the ____ treatment cycle, and the improvements continued for ____ cycle(s).
ANSWER CARD INSTRUCTIONS
Testing and Grading Procedures
Please photocopy the test form for additional test takers.
/Ascend Media Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of 290-000-05-022-H01. The program is available for CE credit through December 1, 2006.
Answer card and evaluation form for Pharmacists follow on page S502.
To provide participants with an overview of premenstrual disorders and the diagnostic and therapeutic strategies for managing their symptoms.
This activity is intended for pharmacists, pharmacy directors, primary care physicians, gynecologists, medical directors, and other managed care decision makers.
After participating in this activity, participants should be better able to:
CONTINUING PHARMACY EDUCATION ACCREDITATION
/Ascend Media Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of 290-000-05-022-H01. Release Date: December 1, 2005. Expiration Date: December 1, 2006.
This program is supported by an educational grant from Berlex Pharmaceuticals.
The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.